stockrowNeuphoria Therapeutics Inc.
NEUP Healthcare Biotechnology
Neuphoria Therapeutics Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.2 million, down 92.5% from fiscal 2025.
- Revenue
- −107.3%
- EPS
- +83.6%
- Free cash flow
- +133.9%
Quarter to June 2026, against a year earlier
Follow NEUP
Alert me
Neuphoria Therapeutics Inc. (NEUP) EV/Sales
As of 6 November 2026, Neuphoria Therapeutics Inc. (NEUP) trades at a EV/Sales of −0.4×. Over the past ten years it has ranged from −17.0× (August 2024) to 1,969× (October 2022); the current reading is higher than 17% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | −0.1× | — |
| FY2023 | 543× | (61.42%) |
| FY2022 | 1,408× | 159.23% |
| FY2020 | 543× | 0.00% |
| FY2019 | 543× | 0.00% |
| FY2018 | 543× | 0.00% |
| FY2017 | 543× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2025 | −0.1× | — |
| Mar 2025 | −0.4× | — |
| Dec 2024 | 2.1× | (99.61%) |
| Jun 2023 | 543× | (61.42%) |
| 5 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| VAXX Vaxxinity, Inc. compare | −94.2× |
| ABOS Acumen Pharmaceuticals, Inc. compare | −25.4× |
| ATYR aTyr Pharma, Inc. compare | −3.5× |
| NEUP Neuphoria Therapeutics Inc. | −0.4× |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| MRKR MARKER THERAPEUTICS, INC. compare | 1.9× |
| KYNB Kyntra Bio Inc compare | 15.5× |
| PLUR Pluri Inc. compare | 32.0× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)